JP2012525432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525432A5 JP2012525432A5 JP2012508753A JP2012508753A JP2012525432A5 JP 2012525432 A5 JP2012525432 A5 JP 2012525432A5 JP 2012508753 A JP2012508753 A JP 2012508753A JP 2012508753 A JP2012508753 A JP 2012508753A JP 2012525432 A5 JP2012525432 A5 JP 2012525432A5
- Authority
- JP
- Japan
- Prior art keywords
- her3
- antibody
- heregulin
- binds
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 23
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 23
- 108090000556 Neuregulin-1 Proteins 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 102000048238 Neuregulin-1 Human genes 0.000 claims 8
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 102400000058 Neuregulin-1 Human genes 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17367009P | 2009-04-29 | 2009-04-29 | |
| US61/173,670 | 2009-04-29 | ||
| PCT/US2010/033058 WO2010127181A1 (en) | 2009-04-29 | 2010-04-29 | Improved antibodies immunoreactive with heregulin-coupled her3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012525432A JP2012525432A (ja) | 2012-10-22 |
| JP2012525432A5 true JP2012525432A5 (OSRAM) | 2013-05-30 |
Family
ID=43032570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508753A Pending JP2012525432A (ja) | 2009-04-29 | 2010-04-29 | ヘレグリン共役型ｈｅｒ３と免疫反応性の改善された抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US8362215B2 (OSRAM) |
| EP (1) | EP2425009A4 (OSRAM) |
| JP (1) | JP2012525432A (OSRAM) |
| AU (1) | AU2010242914B2 (OSRAM) |
| CA (1) | CA2759792A1 (OSRAM) |
| IL (1) | IL216014A0 (OSRAM) |
| WO (1) | WO2010127181A1 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20160737T1 (hr) | 2009-12-22 | 2016-07-15 | Roche Glycart Ag | Anti-her3-protutijela i njihove uporabe |
| ES2566602T3 (es) | 2010-04-09 | 2016-04-14 | Aveo Pharmaceuticals, Inc. | Anticuerpos anti-ErbB3 |
| PH12013500333A1 (en) | 2010-08-20 | 2013-04-22 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| EP2635605B1 (en) | 2010-11-01 | 2018-07-25 | Symphogen A/S | Anti-her3 antibodies and compositions |
| SG192844A1 (en) | 2011-03-11 | 2013-09-30 | Merrimack Pharmaceuticals Inc | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
| BR112013022887A2 (pt) | 2011-03-15 | 2016-12-06 | Merrimack Pharmaceuticals Inc | superação de resistência a inibidores de via de erbb |
| DK2699602T3 (en) | 2011-04-19 | 2017-06-06 | Merrimack Pharmaceuticals Inc | BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES |
| ES2643694T3 (es) * | 2011-05-19 | 2017-11-23 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Anticuerpos anti-HER3 humanos y sus usos |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| MX357391B (es) | 2011-09-30 | 2018-07-06 | Regeneron Pharma | Anticuerpos anti-erbb3 y usos de los mismos. |
| JP6169085B2 (ja) | 2011-10-06 | 2017-07-26 | アベオ ファーマシューティカルズ， インコーポレイテッド | 抗ｅｒｂｂ３抗体に対する腫瘍応答の推定 |
| US9220775B2 (en) | 2011-11-23 | 2015-12-29 | Medimmune Llc | Binding molecules specific for HER3 and uses thereof |
| MX2014006731A (es) * | 2011-12-05 | 2015-06-04 | Novartis Ag | Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3) dirigidos al dominio iii y al dominio iv del her3. |
| US20130273029A1 (en) * | 2011-12-05 | 2013-10-17 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
| TW201328706A (zh) * | 2011-12-05 | 2013-07-16 | Novartis Ag | 表皮生長因子受體３（ｈｅｒ３）之抗體 |
| MX2015005757A (es) | 2012-11-08 | 2015-11-18 | Hoffmann La Roche | Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3. |
| SG11201502534UA (en) | 2012-11-08 | 2015-05-28 | Hoffmann La Roche | Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and the beta-hairpin of her4 |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| WO2014123227A1 (ja) | 2013-02-08 | 2014-08-14 | 株式会社医学生物学研究所 | ヒトｎｒｇ１タンパク質に対する抗体 |
| EP2821071A1 (en) | 2013-07-04 | 2015-01-07 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compounds for breast cancer treatment |
| WO2015048008A2 (en) | 2013-09-24 | 2015-04-02 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
| WO2015066543A1 (en) * | 2013-11-01 | 2015-05-07 | Board Of Regents, The University Of Texas System | Targeting her2 and her3 with bispecific antibodies in cancerous cells |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| RU2016148682A (ru) | 2014-05-14 | 2018-06-19 | Ф. Хоффманн-Ля Рош Аг | Антитела против рецептора-3 к эпидермальному ростовому фактору человека (her3), связывающиеся с бета-шпилькой her3 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| JP2018536682A (ja) | 2015-12-11 | 2018-12-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法 |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| WO1998002541A1 (en) * | 1996-07-12 | 1998-01-22 | Genentech, Inc. | Gamma-heregulin |
| US20090087878A9 (en) * | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
| US7125680B2 (en) * | 2001-07-27 | 2006-10-24 | The Regents Of The University Of California | Methods and materials for characterizing and modulating interaction between heregulin and HER3 |
| EP1283053A1 (en) * | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| AU2003243228B2 (en) * | 2002-05-10 | 2009-03-26 | Medimmune, Llc | EphA2 monoclonal antibodies and methods of use thereof |
| US7501494B2 (en) * | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
| US7531649B2 (en) * | 2003-07-18 | 2009-05-12 | The Regents Of The University Of California | Aptamers to human epidermal growth factor receptor-3 |
| US7413868B2 (en) | 2003-11-05 | 2008-08-19 | Trellis Bioscience, Inc. | Use of particulate labels in bioanalyte detection methods |
| HUE032131T2 (en) * | 2005-08-31 | 2017-09-28 | Merck Sharp & Dohme | Constructed anti-IL-23 antibodies |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
-
2010
- 2010-04-29 AU AU2010242914A patent/AU2010242914B2/en not_active Ceased
- 2010-04-29 JP JP2012508753A patent/JP2012525432A/ja active Pending
- 2010-04-29 EP EP10770384A patent/EP2425009A4/en not_active Ceased
- 2010-04-29 US US12/770,674 patent/US8362215B2/en not_active Expired - Fee Related
- 2010-04-29 WO PCT/US2010/033058 patent/WO2010127181A1/en not_active Ceased
- 2010-04-29 CA CA2759792A patent/CA2759792A1/en not_active Abandoned
-
2011
- 2011-10-27 IL IL216014A patent/IL216014A0/en unknown
-
2013
- 2013-01-17 US US13/744,299 patent/US8828388B2/en not_active Expired - Fee Related
-
2014
- 2014-09-02 US US14/475,348 patent/US9321839B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012525432A5 (OSRAM) | ||
| JP7334177B2 (ja) | 抗ｃｄ７３抗体及びその使用 | |
| ES2595091T3 (es) | Composiciones farmacéuticas con resistencia a CEA soluble | |
| JP2008529489A5 (OSRAM) | ||
| TW200639181A (en) | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof | |
| Friedländer et al. | ErbB-directed immunotherapy: antibodies in current practice and promising new agents | |
| WO2008017963A3 (en) | Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof | |
| JP2012523848A5 (OSRAM) | ||
| CA2749846A1 (en) | Methods of determining patient response by measurement of her-3 | |
| JP2008538289A5 (OSRAM) | ||
| JP2008508903A5 (OSRAM) | ||
| JP2020534830A5 (OSRAM) | ||
| JP2013506428A5 (OSRAM) | ||
| PH12012502376A1 (en) | Modified antigen binding molecules with altered cell signaling activity | |
| JP2012515226A5 (OSRAM) | ||
| JP2016500655A5 (OSRAM) | ||
| JP2008520186A5 (OSRAM) | ||
| JP2017519501A5 (OSRAM) | ||
| IL186948A0 (en) | Monoclonal antibodies and methods for their use in the detection of cervical disease | |
| JP2013527761A5 (OSRAM) | ||
| TNSN06126A1 (en) | Antigen binding molecules with increased fc receptor binding affinity and effector function | |
| NZ597067A (en) | Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer | |
| JP2017526339A5 (OSRAM) | ||
| JP2009545325A5 (OSRAM) | ||
| JP2005225884A5 (OSRAM) |